Segment Reporting (Tables)

6 Months Ended

Jul. 03, 2026

Schedule of Segment and Consolidated Net Income, Including Significant Segment Expenses

The segment and consolidated net income, including significant segment expenses were as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Revenues	$	628,690	$	568,261	$	1,239,502	$	1,123,708
Less:
Cost of goods sold	20,657		19,470		40,610		38,642
Drug discovery	18,252		21,357		37,728		39,610
Development	150,522		134,159		286,237		287,376
Selling, general, and administrative	127,413		112,931		250,283		233,706
Other segment items(1)	63,378		66,718		124,616		124,134
Interest income	(14,210)		(16,789)		(30,337)		(35,865)
Provision for income taxes	50,628		45,567		107,848		91,641
Segment and consolidated net income	$	212,050	$	184,848	$	422,517	$	344,464

_________________

(1) Other segment items include stock-based compensation, other research and development expenses, including the allocation of general corporate costs to research and development services and development cost reimbursements in connection with certain of our collaboration arrangements, and other income (expenses), net.